![](/img/cover-not-exists.png)
352PEarly safety from a phase I, multicenter, open-label, dose de-escalation study of talimogene laherparepvec (T-VEC) in Japanese patients (pts) with unresectable stage IIIB-IV melanoma (MEL)
Yamazaki, N, Koga, H, Kojima, T, Tsutsumida, A, Namikawa, K, Yi, M, Mera, K, Pickett-Gies, CVolume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy439.007
Date:
November, 2018
File:
PDF, 79 KB
2018